Skip to main content

Table 3 Serum PG, G-17 and status of HP in each group

From: Clinical applicability of a new scoring system for population-based screening and risk factors of gastric cancer in the Wannan region

Group (n) PGI (ng/ml) PGII (ng/ml) PGR G-17 (mmol/l) Hp (+)
n (%)
Non atrophic gastritis group (655) 130.34 ± 68.33 13.95 ± 7.74 10.68 ± 5.39 5.53 (2.95, 10.56) 284 (43.36)
Atrophic gastritis group (52) 122.27 ± 52.77* 18.84 ± 11.13* 7.37 ± 2.78* 5.53 (4.24, 9.02) 26* (50.00)
Gastric ulcer group (109) 169.85 ± 84.51* 20.09 ± 11.50* 9.69 ± 4.85 5.96 (3.77, 11.25)* 71* (65.14)
Non-neoplastic polyp group (79) 132.37 ± 62.39 19.37 ± 11.58* 8.49 ± 5.62* 6.39 (4.53, 10.95)* 39 (49.37)
Precancerous lesion group (94) 109.70 ± 60.57* 18.08 ± 10.49* 6.95 ± 3.56* 6.65 (4.06, 13.02)* 58* (61.70)
Early cancer group (12) 98.61 ± 72.45* 17.26 ± 5.81* 6.13 ± 4.11* 5.89 (4.96, 13.24)* 7* (58.33)
Advanced cancer group (15) 66.30 ± 29.97* 19.70 ± 8.84* 4.54 ± 4.95* 10.6 (4.83, 16.26)* 10* (66.67)
P  < 0.001  < 0.001  < 0.001 0.003  < 0.001
  1. GC gastric cancer, Hp Helicobacter pylori, PGR pepsinogen ratio, G-17 gastrin-17
  2. Compared with non-atrophic gastritis group, *P < 0.05